Apimeds Pharmaceuticals U... (APUS)
NYSE: APUS
· Real-Time Price · USD
2.13
-0.14 (-6.17%)
At close: Aug 22, 2025, 12:31 PM
Apimeds Pharmaceuticals US Inc Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -1.37M | -1.28M | -1.56M | -1.36M | -962.78K | -747.44K | -254.55K | -150.39K | -122.57K | -66.19K |
Interest Income | 666.00 | 2.82K | 8.38K | 10.49K | 9.97K | 7.81K | 2.23K | n/a | n/a | n/a |
Pretax Income | -1.5M | -1.39M | -1.65M | -1.42M | -1.01M | -777.69K | -285.32K | -175.3K | -139.23K | -74.59K |
Net Income | -1.5M | -1.39M | -1.65M | -1.42M | -1.01M | -777.69K | -285.32K | -175.3K | -139.23K | -74.59K |
Selling & General & Admin | 1.37M | 1.28M | 1.53M | 1.34M | 914.79K | 648.89K | 122.44K | 15.29K | 9.9K | 4.07K |
Research & Development | n/a | n/a | 28.55K | 25.55K | 47.99K | 98.54K | 132.11K | 135.11K | 112.67K | 62.12K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 1.37M | 1.28M | 1.56M | 1.36M | 962.78K | 747.44K | 254.55K | 150.39K | 122.57K | 66.19K |
Interest Expense | 128.84K | 117.72K | 95.15K | 70.6K | 56.73K | 38.07K | 33K | 24.91K | 16.66K | 8.41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 1.37M | 1.28M | 1.56M | 1.36M | 962.78K | 747.44K | 254.55K | 150.39K | 122.57K | 66.19K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 11.57M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M |
Shares Outstanding (Diluted) | 11.57M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M |
EPS (Basic) | -0.13 | -0.12 | -0.14 | -0.12 | -0.09 | -0.07 | -0.02 | -0.02 | -0.01 | -0.01 |
EPS (Diluted) | -0.12 | -0.11 | -0.13 | -0.11 | -0.08 | -0.06 | -0.02 | -0.01 | -0.01 | -0.01 |
EBITDA | -1.37M | -1.27M | -1.55M | -1.35M | -952.81K | -739.63K | -252.32K | -150.39K | -122.57K | -66.19K |
EBIT | -1.37M | -1.27M | -1.55M | -1.35M | -952.81K | -739.63K | -252.32K | -150.39K | -122.57K | -66.19K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |